MIDOS: A MICRORNA BIODOSIMETER

点击翻译按钮获取中文摘要

ChromoLogic will team with the experienced groups at the University of Pittsburgh, Wake Forest University, Sarcoma Oncology and City of Hope Cancer Center, and Charles River-Laval to plan and carry out the studies. Specifically, the Contractor plans to validate ChromoLogic’s miRNA panel to predict neutropenia in the clinic (sarcoma patients), and obtain FDA approval (Phase 1); validate ChromoLogic’s miRNA panel to predict fibrosis in the clinic (head and neck cancer patients) and obtain FDA approval (Phase 1); and submit pre-EUA for panels to predict ARS (neutropenia) and DEARE (fibrosis) (Phase 2).